

Kyphoplasty versus vertebroplasty for painful osteoporotic vertebral compression fractures—which one is better? A systematic review and meta-analysis

Huilin Yang, Tao Liu, Jun Zhou, Bin Meng, Genlin Wang and Xuesong Zhu

Int J Spine Surg 2013, 7 () e45-e57 doi: https://doi.org/10.1016/j.ijsp.2013.03.001 https://www.ijssurgery.com/content/7/e45

This information is current as of May 17, 2025.

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://ijssurgery.com/alerts

The International Journal of Spine Surgery 2397 Waterbury Circle, Suite 1, Aurora, IL 60504, Phone: +1-630-375-1432 © 2013 ISASS. All Rights Reserved.



Downloaded from https://www.ijssurgery.com/ by guest on May 17, 2025



Available online at www.sciencedirect.com





International Journal of Spine Surgery 7 (2013) e45-e57

Kyphoplasty versus vertebroplasty for painful osteoporotic vertebral compression fractures—which one is better? A systematic review and meta-analysis

Huilin Yang, MD, PhD*, Tao Liu, MD, PhD, Jun Zhou, MD, PhD, Bin Meng, MD, PhD, Genlin Wang, MD, PhD, Xuesong Zhu, MD

Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China

Abstract

Background: Whether kyphoplasty or vertebroplasty is better for painful osteoporotic vertebral compression fracture is a widely debated issue. Studies on the comparison of the 2 approaches are relative limited and a wide variation exists in the patient population, study design, and results. These factors make it difficult for workers in this field to know the exact value of the 2 approaches.

Objective: To perform a systematic review and meta-analysis to compare the clinical outcomes and complications of kyphoplasty versus vertebroplasty for painful osteoporotic vertebral compression fractures (OVCF).

Study design: A systematic review and meta-analysis.

Methods: MEDLINE, EMBASE, and other databases were searched for all the relevant original articles published from January 1987 to September 2012 comparing kyphoplasty with vertebroplasty for painful OVCF. The following outcomes were mainly evaluated: visual analog scale (VAS), vertebral height, kyphosis angle, new vertebral fractures, and cement leakage.

Results: A total of 15 articles fulfilled all the inclusion criteria. The baseline characteristics such as sex, age, and number of prevalent fractures were comparable for both groups (P > .05). VAS score for the kyphoplasty group was significantly more than that for the vertebroplasty group at 1-3 days, 3 months, 6 months, 1 year, and 2 years after surgery (P < .05). Vertebral height in the kyphoplasty group was significantly higher than the vertebroplasty group at 3 months, 6 months, and 2 years (P < 0.05). Kyphosis angle in the kyphoplasty group was significantly lower at 3 months, 6 months, and 2 years (P < 0.05). The occurrence of new vertebral fractures in the kyphoplasty group had no significant difference with the vertebroplasty group at 3 months, 6 months, and 2 years (P > 0.05). The occurrence of cement leakage was significantly lower in the vertebroplasty group (P < 0.05).

Limitations: The main limitations of this review are that the demographics and comorbidities of study participants were not reported. These possible sources of heterogeneity could not be examined.

Conclusions: Percutaneous kyphoplasty is better than vertebroplasty in the treatment of painful OVCF. Kyphoplasty had better improvement at VAS score, vertebral height, and kyphosis angle with lower occurrence of cement leakage.

© 2013 Published by Elsevier Inc. on behalf of ISASS - The International Society for the Advancement of Spine Surgery.

Keywords: Vertebroplasty; Kyphoplasty; OVCF; META

temperature cement delivery system (ITCDS). They have contributed a lot to advancement of KP by promoting the popularization and application of these new ideas. They are to be commended for this and we at the Journal encourage other authors interested in documenting their own experiences with blazing a trail for new treatments to share their observations with us. Hansen Yuan, MD, Editor-in-Chief, International Journal of Spine Surgery.

^{*}Corresponding author: Huilin Yang, Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi St, Suzhou 215006, China.

E-mail addresses: suzhouspine@163.com, yhlwl2001@yahoo.com

2211-4599 © 2013 Published by Elsevier Inc. on behalf of ISASS – The International Society for the Advancement of Spine Surgery. http://dx.doi.org/10.1016/j.ijsp.2013.03.001

Dr. Yang et al. have performed a valuable service to China by bringing research about the newest treatment methods for vertebral compression fractures to their region. Perhaps there will come a time when globalized standards in healthcare will allow for the cutting edge of techniques and technologies to arrive to all corners of the globe simultaneously. In the meantime, however, pioneers like Dr. Yang and his colleagues are working hard to bring the best possible care to patients in their own locale. The Yang group has conducted both basic and clinic researches on kyphoplasty (KP) and put forward a series of SUZHOU theories, such as concept and diagnosis of osteoporotic vertebral compression fracture nonunion and incremental

Osteoporotic vertebral compression fractures (OVCF) are one of the most common skeletal fractures¹ and are increasing in frequency in our ageing population because of the growing prevalence of osteoporosis. Vertebral fractures often result in significant pain that often leads to decreased mobility, loss of independence, and subsequent loss of bone density associated with inactivity. Vertebral fractures can also have negative effects on the respiratory and digestive systems owing to resultant postural deformity.² There is a significant increased mortality rate in patients with vertebral fractures treated conservatively compared with age-matched controls in the literature.³ The 5-year survival rate for patients with compression fractures is 61%, as compared with 76% in age-matched peers.⁴

The treatment for OVCF is essential, but it is a difficult problem. The traditional conservative treatments such as bed rest, pain-killers, and osteoporosis drugs and the use of orthopedic appliances, etc,¹ can cause hypostatic pneumonia, bed sores, urinary tract stones or deep vein thrombosis, which increase the suffering of the patients,⁵ and cannot improve the vertebral height of the fractured. The open surgery such as posterior short-segment pedicle screw fixation may lead to bigger surgical trauma, longer surgical time, and more blood loss. Because of osteoporosis, the grip force for pedicle screw is not strong enough. The internal fixation is prone to loosening, displacement, or settlements which often lead to fixation failure.^{4,6} Therefore, open surgery is a relative contraindication for patients with OVCF.

Since the late 1980s, 2 minimally invasive surgical treatments: vertebroplasty (VP) and kyphoplasty (KP) have been gradually introduced that changed the treatment of OVCF. In 1987, Galibert et al.⁷ used vertebroplasty for the first time to treat vertebral hemangioma, and later in 1988, percutaneous vertebroplasty (PVP) was widely used in primary and secondly painful osteoporotic vertebral fractures around the world.⁸ Guided by X-Ray, vertebroplasty involves injecting polymethylmethacrylate (PMMA) bone cement into the fractures of the vertebral body percutaneously to enhance the strength of the vertebra and stiffness and prevent further vertebral collapse and deformity, and effectively relieve pain. Kyphoplasty was introduced in 1998 as an alternative. Unlike VP, it created a cavity in the vertebral body with a balloon (inflatable bone tamp) before injecting PMMA bone cement. Both PVP and percutaneous kyphoplasty (PKP) can quickly relieve spinal compression fractures in osteoporotic patients with pain, reduced analgesic drug dependence and improve the quality of life in patients with OVCF.^{1–7,9} PVP and PKP become the main surgical treatment for OVCF patients.

Although extensive research on the 2 approaches has been done, no consensus has been reached as to whether kyphoplasty or vertebroplasty is better. Furthermore, studies on the comparison of the 2 approaches are relatively limited and a wide variation in patient population, study design, and results exists. These factors make it difficult for workers in this field to know the exact value of the 2 approaches. Meta-analysis represents a powerful tool to summarize the findings in the literature by taking into account and enabling analysis of the differences between studies.^{10,11} Thus, the purpose of our study is to perform a systematic review and meta-analysis to compare the clinical outcomes and complications of kyphoplasty versus vertebroplasty for painful OVCF.

Materials and methods

Literature search

A comprehensive computer literature search of abstracts¹² of studies in human subjects was performed to identify articles about kyphoplasty and vertebroplasty for painful OVCF. The MEDLINE and EMBASE databases, from January 1987 to September 2012, were searched with the following keywords: ("Kyphoplasty" OR "Vertebroplasty"). No language restrictions were applied.

Other databases, such as Web of Knowledge, EBSCO, ScienceDirect, SpringerLink, Scopus, and The Cochrane Library, were also checked for relevant articles with the same keywords. We also searched the abstracts of American Academy of Orthopaedic Surgeons annual meeting (2006– 2011: (http://www.aaos.org/education/anmeet/libscip.asp)). The list of articles was supplemented with extensive cross-checking of the reference lists of all retrieved articles.

Selection of studies

Two reviewers (L.T. and X.W.) independently assessed potentially eligible studies. The study selection was accomplished through 2 levels of study screening. At the level 1 screening, abstracts were reviewed for the following exclusion criteria: case reports, letters, editorial, comments, reviews, and articles that did not include raw data. Full articles were then obtained for all studies accepted at level 1 screening and any citations for which a determination could not be made from the abstract. If the study was not reported in full journal publications, we contacted the authors for the full text or additional information needed. For level 2 screening, the inclusion criteria were as follows: any randomized, quasi-randomized controlled clinical trials, prospective or retrospective cohort study of KP versus VP for painful OVCF in adults.^{1,2} The aim of the study was to compare KP with VP for painful OVCF.³ The patients included were all patients with OVCF. If the study included not only patients with OVCF but also other patients, such as those with metastasis, only patients with OVCF were selected if the results could be differentiated. When data or subsets of data were presented in more than one article, the article with the most details or the most recent article was chosen. The studies were excluded if the results were presented in combination and could not be differentiated for performance assessment.

Data extraction

The same observers independently extracted relevant data from each article by using a standardized form. Observers were not blinded with regard to the information about the journal name, the authors, the authors' affiliation, or year of publication, as this had been shown to be unnecessary.¹³ To resolve disagreement between reviewers, a third reviewer (C.T.) assessed all discrepant items, and the opinion of the majority was used for analysis.

Common characteristics about studies

Author's country; year of publication; number of patients; mean age; study design; research center; and duration of fracture.

Study design characteristics

A methodological quality assessment scheme recommended by the Cochrane library¹⁴ was used to extract relevant study design characteristics for each study. In this scheme, there are 11 items and the answer to each item was graded as "Y," "?," or "N," respectively indicating that the quality criteria were met for the item ("yes"), or possibly or only partially met for the item ("Possible, partial"), or not met ("No").

Clinical characteristics about studies

- (1) *Perioperative outcomes*: these included volume of cement and operative time.
- (2) *Clinical outcomes:* these included VAS, Oswestry Disability Index (ODI), and Euro Quality of Life–5 Dimensions (EQ-5D).
- (3) Radiographic outcomes: these included vertebral height (mm), vertebral height rate (%) (It was expressed as the percentage of the vertebra height for the fractured vertebra compared with the height for the adjacent normal vertebrae(%)), and kyphosis angle.
- (4) *Complications outcomes:* these included adjacent new vertebral fractures and cement leakage.

The primary outcomes were VAS, vertebral height, kyphosis rate, adjacent new vertebral fractures, and cement leakage.

Subgroup analysis

Analysis of the outcomes was divided to subgroups according to the time of outcome assessment, if possible. The times of outcome assessment were 1 day, 3 days (or 1–3 days), 1 week, 2 weeks (or 1–2 weeks), 1 month, 2 months, 3 months, 6 months, 1 year, and 2 years.

Statistical analysis

Common characteristics were summarized by using basic descriptive statistics (simple counts and means). Clinical characteristics were synthesized via meta-analytic pooling of each group results. Meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines.^{15–17} Statistical analysis of dichotomous variables was carried out using odds ratios (ORs) as the summary statistic, whereas continuous variables were analyzed using the weighted mean difference (WMD); both were reported with 95% confidence intervals (CIs). The Mantel-Haenszel method was used to combine the ORs and the inverse-variance method was used to combine the WMDs for the clinical characteristics.

Heterogeneity was assessed by χ^2 test and the I^2 statistic. A fixed-effects model was used to calculate summary statistics if no statistically significant (P < .05) heterogeneity was found among similar comparisons, whereas if statistically significant (P > .05) heterogeneity was found, a random-effects model was used. We constructed a funnel plot to explore the possibility of publication bias. All Pvalues are 2 sided. Results were considered to be statistically significant at a P value of less than 0.05.

All analyses were performed by using Microsoft Excel 2003 (Microsoft, Seattle, Wash), SPSS 13.0 for Windows (SPSS, Chicago, III), and RevMan5.0 (Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.). RevMan5.0 is a freeware software produced by The Cochrane Collaboration, and can be downloaded from the website "(http://www.cc-ims.net/RevMan/RevMan5)."

Results

Literature search and selection of studies

After the computerized search was performed and reference lists were extensively cross-checked, about 3034 abstracts were identified. Of these, 2951 were rejected after level 1 screening (reviewing the abstracts). Of the remaining 83 articles, 67 relevant articles were excluded after we read the full texts or additional information of these articles because (a) the articles were not randomized, quasi-randomized controlled clinical trials, perspective, or retrospective cohort study (n = 50); (b) The aim of the articles was not to compare KP with VP for painful OVCF (n = 9); (c) The patients included were not patients with OVCF or the relevant data could not be extracted (n = 4); (d) The studies did not include raw data (n = 5). At last 15 articles^{18–32} including 15 studies fulfilled all the inclusion criteria and were selected for data extraction and analysis.

Common characteristics of studies

The studies took place in one of 9 countries (China,³ Australia,¹ Canada,¹ Spain,¹ Japan,¹ Germany,³ Italy,³ USA,¹ and Slovenia¹). All the studies were single-center studies including 1RCT, 5 NRCT, 4 prospective cohort studies, and 5 retrospective cohort studies. There were total 1151 patients in the selected studies. Of them, 627 patients

were treated by vertebroplasty and 524 patients underwent kyphoplasty. The age ranged from 62 to 78 years for the vertebroplasty group and 64 to 76.9 years for the kyphoplasty group.

Table 1 presents the detail information about the common characteristics of the included data sets.

Study design characteristics

Most studies had a suboptimal design with regard to treatment concealment (question 1:93.3% for "no" responses), the intention to treat analysis (question 2:93.3% for "no" and "?" responses), outcome assessors blind (question 3:80% for "no" responses), and doubleblind (questions 5 and 6, 100% for "no" and "?" responses). But, as for baseline characteristics, care programmes other than the trial options, inclusion and exclusion criteria, outcome measures and follow-up time etc, most studies were optimally designed (60% for "yes" responses to question 4; 53% to question 7; 60% to questions 8 and 9; 86.7% to questions 10 and 11). In fact, questions 1-3 and 5-6 were more concerned with study method whereas questions 4 and 7-11 were more concerned with clinical data, so questions 4 and 7-11 were more important. If the studies were ideally designed according to these questions, the clinical result would be correct and credible.

Table 2 presents the detail information about study design characteristics of the included data sets.

Perioperative outcomes

(1) Volume of cement

The volume of cement injected for the vertebroplasty group was significantly less than the kyphoplasty group (P < .05, WMD -0.75 [-0.93, -0.57]).

(2) Operative time

The operative time for the vertebroplasty group was significantly less than the kyphoplasty group (P < .05, WMD -3.44 [-4.94, -1.94]).

Table 3 presents the results of meta-analysis of perioperative outcome measures.

Clinical outcomes

(1) VAS

At baseline, the VAS score was similar in both groups (P > .05, WMD 0.14 [-0.01, 0.28]). At 1–3 days, 1–2 weeks, 1 month, 3 months, 6 months, 1 year, and even 2 years after operation, the VAS score for the vertebroplasty group was significantly more than the kyphoplasty group (P < .05, WMD was 0.18 [0.02, 0.34], 0.45 [0.15, 0.75], 0.42 [0.14, 0.70], 0.89 [0.72, 1.06], 1.24 [1.07, 1.41], and 1.01 [0.41, 1.60], respectively) (Fig. 1).

Common characteristics about the included data sets	out the included data sets								
					Number of patients	atients		Age	
References	Country	Published year	Study design	Research center	V	K	Total	Λ	K
Liu et al. ¹⁸	Chinese Taiwan	2010	RCT	1	50	50	100	74.3	72.3
Kumar et al. ¹⁹	Canada	2010	NRCT	1	28	24	52	78	73
Santiago et al. ²⁰	Spain	2010	PC	1	30	30	60	73.0	65.9
Yan et al. ²¹	China	2010	RC	1	94	98	192	77.2	76.9
Hiwatashi et al. ²²	Japan	2008	RC	1	99	40	106	LL	75
Schofer et al. ²³	Germany	2009	PC	1	30	30	60	72.5	73.8
Lovi et al. ²⁴	Italy	2009	NRCT	1	118	36	154	67.6	67.6
Zhou et al. ²⁵	China	2008	RC	1	56	32	88	62	49
Frankel et al. ²⁶	USA	2007	RC	1	19	17	36	72	70
De Negri et al. ²⁷	Italy	2007	NRCT	1	10	11	21	NR	NR
Grohs et al. ²⁸	Austria	2005	NRCT	1	23	28	51	70	70
Pflugmacher et al. ²⁹	Germany	2005	PC	1	20	22	42	72.3	71.2
Movrin et al. ³⁰	Slovenia	2010	NRCT	1	27	46	73	72.9	67.8
Röllinghoff et al. ³¹	Germany	2008	PC	1	45	45	06	NR	NR
Pilát et al. ³²	Italy	2007	RC	1	11	15	26	NR	NR
RCT, randomized controllec reported or could not get.	d clinical trial; NRCT, nonr	andomized controlled clini	ical trial; PC, prospectiv	RCT, randomized controlled clinical trial; NRCT, nonrandomized controlled clinical trial; PC, prospective cohort study; RC, retrospective cohort study; V, vertebroplasty group; K, kyphoplasty group; NR, not reported or could not get.	ctive cohort study	r; V, vertebropla	ısty group; K, kyp	hoplasty group;	NR, not

Table

Table 2
Study design characteristics of the included data sets

Questions studies	Scores										
	Question (1)	Question (2)	Question (3)	Question (4)	Question (5)	Question (6)	Question (7)	Question (8)	Question (9)	Question (10)	Question (11)
Liu et al. ¹⁸	Y	?	Y	Y	Ν	N	Y	?	Y	Y	Y
Kumar et al. ¹⁹	Ν	Y	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y
Santiago et al. ²⁰	Ν	?	?	Y	Ν	Ν	Y	Y	Y	Y	Υ
Yan et al. ²¹	Ν	?	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y
Hiwatashi et al.22	Ν	Ν	Ν	?	Ν	Ν	Ν	?	Y	Y	Ν
Schofer et al. ²³	Ν	?	Ν	Y	Ν	Ν	Y	Y	Y	Y	Υ
Lovi et al. ²⁴	Ν	?	Ν	Ν	Ν	Ν	?	Y	Y	Y	Y
Zhou et al. ²⁵	Ν	Ν	Ν	?	Ν	Ν	Ν	?	?	?	Υ
Frankel et al. ²⁶	Ν	Ν	Ν	?	Ν	Ν	?	?	Ν	?	?
De Negri et al. ²⁷	Ν	Ν	Ν	?	Ν	Ν	Ν	?	?	Y	Y
Grohs et al.28	Ν	?	Y	Y	Ν	Ν	Ν	Y	Y	Y	Y
Pflugmacher et al. ²⁹	Ν	?	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y
Movrin et al. ³⁰	Ν	?	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y
Röllinghoff et al.31	Ν	?	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y
Pilát et al. ³²	Ν	Ν	Ν	?	Ν	Ν	Ν	?	Y	Y	Y
N (total)	14	5	12	2	15	15	5	0	1	0	1
? (total)	0	9	1	5	0	0	2	6	2	2	1
Y (total)	1	1	2	9	0	0	8	9	9	13	13

Questions 1–11 were the 11 questions in the Methodological quality assessment scheme.²¹ Data were the responses to these questions for each article and the number of response "N," "?," or "Y" for each question.

 Table 3

 Results of meta-analysis of perioperative outcome measures

Outcomes or subgroups	No. of studies	No. of patients	Statistical method	Effect estimate $(95\% \text{ CI})^{\dagger}$	P value
(1) Volume of cement(2) Operative time	6	615	WMD	-0.75 [-0.93, -0.57]	<.05 [*]
	2	188	WMD	-3.44 [-4.94, -1.94]	<.05 [*]

WMD, indicated weighted mean difference; CI, confidence interval.

If effect estimate is positive (>0), it means vertebroplasty group is more than kyphoplasty group. If it is negative (<0), it means vertebroplasty group is less than kyphoplasty group. Whether it is significant lies on the P value.

*Statistically significant.

[†]Effect estimate.

(2) ODI

ODI: The ODI for the vertebroplasty group was significantly more than that for the kyphoplasty group at baseline (P < .05, 3.56 [1.61, 5.51]). At 1 week 1 month, 3 months, and 1 year after operation, it was also significantly more than that of the kyphoplasty group (P < .05, WMD was 10.40 [8.06, 12.74], 2.82 [0.72, 4.91], 4.31 [1.95, 6.67], and 4.43 [-1.27, 10.13] respectively). At 6 months and 2 years after operation, there was no significant difference between both groups (P > .05, WMD was 0.45 [-0.82, 1.72] and -4.00 [-11.57, 3.57], respectively).

(3) EQ-5D

The EQ-5D score for the vertebroplasty group was significantly less than the kyphoplasty group at baseline, 1 week, 3 months, and 10 months after operation (P < 0.05, WMD was -0.08 [-0.12, -0.03], -0.37 [-0.41, -0.33], -0.15 [-0.18, -0.12], and -0.24 [-0.28, -0.21] respectively).

Table 4 presents the results of meta-analysis of clinical outcome measures.

Radiographic outcomes

(1) Vertebral height (mm)

The vertebral height for the vertebroplasty group was similar to that of the kyphoplasty group at baseline (P > 0.05, WMD 0.06 [-0.22, 0.33]), but after the operation, it was significantly less than that of the kyphoplasty group (P < 0.05, WMD -2.38 [-2.67, -2.08). The improvement in the vertebral height for the vertebroplasty group was significantly less than the kyphoplasty group (P < .05, WMD -2.00 [-2.75, -1.25]).

(2) Vertebral height rate (%)

The vertebral height rate for the vertebroplasty group was similar to the kyphoplasty group at baseline (P > .05, WMD -0.65 [-3.52, 2.23]), but after the operation, it was significantly less than the kyphoplasty group (P < 0.05, WMD -17.75 [-20.73, -14.77]). The improvement in the vertebral height rate for the vertebroplasty group was significantly less than the kyphoplasty group (P < 0.05, WMD -7.25 [-8.45, -6.05]) (Fig. 2).

(3) Kyphosis angle

The kyphosis angle for the vertebroplasty group was similar to the kyphoplasty group at baseline (P > .05, WMD -1.01 [-1.98, -0.04]), but after the operation, it was significantly more than the kyphoplasty group (P < 0.05, WMD 4.25 [3.52, 4.98]). The improvement in the kyphosis angle for the vertebroplasty group was significantly less than the kyphoplasty group (P < .05, WMD -5.65 [-6.13, -5.17]) (Fig. 3).

Table 5 presents results of meta-analysis of radiological outcome measures.

Complications outcomes

(1) Adjacent new vertebral fractures

There was no significant difference between both groups at 6 months and 1 year after operation (P > .05, WMD was 0.14 [0.02, 1.21] and 1.78 [0.91, 3.49], respectively) (Fig. 4).

(2) Cement Leakage

To disc: The cement leakage to disc for the vertebroplasty group was significantly more than the kyphoplasty group (P < .05, OR 2.10 [1.31, 3.37]).

Paravertebral: The paravertebral cement leakage in the vertebroplasty group was significantly more than the kyphoplasty group (P < .05, OR 2.36 [1.27, 4.40]).

Total: The total cement leakage in the vertebroplasty group was also significantly more than the kyphoplasty group (P < .05, OR 2.15 [1.35, 3.44]).

Fig. 5 presents the forest plots of the meta-analysis of cement leakage.

Table 6 shows the results of meta-analysis of complication outcome measures.

Discussion

The results of this meta-analysis have shown that the volume of cement injected and the operative time for the vertebroplasty group was significantly less than the kyphoplasty group. At baseline, the VAS scores were similar in both groups. At 1–3 days, 1–2 weeks, 1 month, 3 months, 6 months, 1 year, and

Study or Subgroup		oropla	-	ky ph Mean		-	Weight	Mean Difference	Mean Difference
	Mean		Total		SD		Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
De Negri 2207	8.36	1.21	10	8.3	1.25	11	1.8%	0.06 [-0.99, 1.11]	
Grohs 2005	7.8	2.35	23	7.4	1.5	28	1.7%	0.40 [-0.71, 1.51]	t
Kumar 2010	8	0.4	28	7.5	0.5	24	32.9%	0.50 [0.25, 0.75]	•
Liu 2010	7.9	0.7	50	8	0.8	50	23.5%	-0.10 [-0.39, 0.19]	+
									Ļ
Lovi 2009	8.4	5	118	8	5	36	0.6%	0.40 [-1.47, 2.27]	
Movirin2010	8.7	5	27	8.8	5	46	0.4%	-0.10 [-2.48, 2.28]	Ť
Pilat 2007	8.9	5	11	8.5	5	15	0.1%	0.40 [-3.49, 4.29]	+
Santiago 2010	8.6	5	30	8.6	5	30	0.3%	0.00 [-2.53, 2.53]	+
Schofer 2009	8.3	2.6	30	8.2	2.3	30	1.3%	0.10 [-1.14, 1.34]	I
Yan 2010	8.21	1.43	94	8.18	1.09	98	15.7%	0.03 [-0.33, 0.39]	•
Zhou 2008	8.4	0.5	56	8.5	0.8	32			
21100 2006	0.4	0.0	50	0.0	0.0	32	21.770	-0.10 [-0.41, 0.21]	
Total (95% CI)			477			400	100.0%	0.14 [-0.01, 0.28]	
Heterogeneity: Chi ² =	13.67 df	- 10/0	2 - 0 1	a). 12 - 0	70/				
				9), 1 2	.1 70				-100 -50 0 50 1
Test for overall effect:	Z = 1.86	(P = 0.	06)					F	Favours experimental Favours control
Dist 4 Televis	ventel			la m b		4			
3.2 at 1-7days	vertei	propla	•		noplas	τy		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI IV, Fixed, 95% CI
Grohs 2005	3	1	23	3.5	1	28	8.4%	-0.50 [-1.05, 0.05]	•
Kumar 2010	4.7	0.5	28	3.3	0.6	24	27.9%	1.40 [1.10, 1.70]	
iu 2010	2.3	0.5	50	2.6	0.6	50	54.7%	-0.30 [-0.52, -0.08]	■
		2							
Movirin2010	2.3		27	2	2	46	2.8%	0.30 [-0.65, 1.25]	
Pilat 2007	2.7	2	11	3.1	2	15	1.1%	-0.40 [-1.96, 1.16]	Ī
Schofer 2009	3	1.6	30	3.2	1.2	30	5.0%	-0.20 [-0.92, 0.52]	
2000	5	1.0	50	0.2	1.4	50	0.070	0.20 [-0.02, 0.02]	
Fotal (95% CI)			169			193	100.0%	0.18 [0.02, 0.34]	
Heterogeneity: Chi ² =	88.60 44	= 5 /P	< 0.00	101\·I2-	= 0/10/				
				501), 1 -	- 34 70				-100 -50 0 50 1
Fest for overall effect:	Z = 2.19	(P = 0.	03)						Favours experimental Favours control
3.3 at 1month	verte	bropla	stv	kypł	hoplas	stv		Mean Difference	Mean Difference
Study Out							Weinh4		
Study or Subgroup	Mean	50	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI IV, Fixed, 95% CI
ovi 2009	3.6	1	118	3.4	1	36	64.8%	0.20 [-0.17, 0.57]	1 📕
			30	3.5					· _
Santiago 2010	4.4	1	30	3.0	1	30	35.2%	0.90 [0.39, 1.41]	I T
Fotal (95% CI)			148			66	100.0%	0.45 [0.15, 0.75]	
, ,	4.70 14	4.0		12 700	,				
Heterogeneity: Chi ² =	4.76, df =	: 1 (P =	: 0.03);	1- = 79%	6				-100 -50 0 50 1
Test for overall effect:	Z = 2.91	(P = 0)	004)					,	
		(ł	Favours experimental Favours control
3.4 at 3months	vorto	bropla	etu	kypk	noplas	tu		Mean Difference	Mean Difference
					-	-			
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% Cl
<u>Study or Subgroup</u>	mean								
			23	3	12	28	22.1%	2 60 [2 00 3 20]	•
Grohs 2005	5.6	1	23	3	1.2	28	22.1%	2.60 [2.00, 3.20]	
Grohs 2005			28	3 3.3	1.2 0.6	28 24		2.60 [2.00, 3.20] -0.20 [-0.55, 0.15]	
Grohs 2005 Kumar 2010	5.6	1						-0.20 [-0.55, 0.15]	• •
Grohs 2005 Kumar 2010	5.6 3.1	1 0.7	28	3.3	0.6	24	64.6%		• •
Grohs 2005 Kumar 2010 Pilat 2007	5.6 3.1	1 0.7	28 11	3.3	0.6	24 15	64.6% 13.3%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58]	• •
Grohs 2005 Kumar 2010 Pilat 2007 Total (95% CI)	5.6 3.1 1.4	1 0.7 1	28 11 62	3.3 1.6	0.6 1	24	64.6%	-0.20 [-0.55, 0.15]	• •
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI)	5.6 3.1 1.4	1 0.7 1	28 11 62	3.3 1.6	0.6 1	24 15	64.6% 13.3%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58]	, ,
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² =	5.6 3.1 1.4 64.34, df	1 0.7 1 = 2 (P	28 11 62 < 0.00	3.3 1.6	0.6 1	24 15	64.6% 13.3%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70]	-100 -50 0 50 11
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² =	5.6 3.1 1.4 64.34, df	1 0.7 1 = 2 (P	28 11 62 < 0.00	3.3 1.6	0.6 1	24 15	64.6% 13.3%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70]	, ,
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect:	5.6 3.1 1.4 64.34, df Z = 2.89	1 0.7 1 = 2 (P (P = 0.	28 11 62 < 0.00 004)	3.3 1.6 001); I² :	0.6 1 = 97%	24 15 67	64.6% 13.3%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70]	-100 -50 0 50 1 Favours experimental Favours control
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths	5.6 3.1 1.4 64.34, df Z = 2.89 vertel	1 0.7 1 = 2 (P (P = 0.	28 11 62 < 0.00 004) sty	3.3 1.6 001); I ² : kyph	0.6 1 = 97%	24 15 67	64.6% 13.3% 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths	5.6 3.1 1.4 64.34, df Z = 2.89	1 0.7 1 = 2 (P (P = 0.	28 11 62 < 0.00 004)	3.3 1.6 001); I ² : kyph	0.6 1 = 97%	24 15 67	64.6% 13.3% 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference	-100 -50 0 50 1 Favours experimental Favours control Mean Difference
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup	5.6 3.1 1.4 64.34, df Z = 2.89 vertel	1 0.7 1 = 2 (P (P = 0.	28 11 62 < 0.00 004) sty	3.3 1.6 001); I ² : kypt <u>Mean</u>	0.6 1 = 97%	24 15 67	64.6% 13.3% 100.0% <u>Weight</u>	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55	$ \begin{array}{r} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas) <u>SD</u> 0.52	28 11 62 < 0.00 004) sty Total 10	3.3 1.6 001); I ² = kyph <u>Mean</u> 0.7	0.6 1 = 97% noplas <u>SD</u> 0.67	24 15 67 ty <u>Total</u> 11	64.6% 13.3% 100.0% <u>Weight</u> 11.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference <u>IV, Fixed, 95% C</u> -0.15 [-0.66, 0.36]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at 6months Study or Subgroup De Negri 2207 Kumar 2010	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5	$ \begin{array}{r} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. bropla: <u>SD</u> 0.52 0.4	28 11 62 < 0.00 004) sty Total 10 28	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7	24 15 67 ty <u>Total</u> 11 24	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] f Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [2.68, 3.32]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at 6months Study or Subgroup De Negri 2207 Kumar 2010	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55	$ \begin{array}{r} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas) 0.52 \\ 0.4 \\ 0.6 \end{array}	28 11 62 < 0.00 004) sty Total 10	3.3 1.6 001); I ² = kyph <u>Mean</u> 0.7	0.6 1 = 97% noplas <u>SD</u> 0.67	24 15 67 ty <u>Total</u> 11	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference <u>IV, Fixed, 95% C</u> -0.15 [-0.66, 0.36]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5	$ \begin{array}{r} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. bropla: <u>SD</u> 0.52 0.4	28 11 62 < 0.00 004) sty Total 10 28	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7	24 15 67 ty <u>Total</u> 11 24	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% -0.15 [-0.66, 0.36] 3.00 [2.68, 3.32] 0.00 [-0.24, 0.24]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Plat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lovi 2009	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas <u>SD</u> 0.52 0.4 0.6 2 \end{array}	28 11 62 < 0.00 004) sty Total 10 28 50 118	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6	0.6 1 = 97% ooplas <u>SD</u> 0.67 0.7 0.6 2	24 15 67 ty <u>Total</u> 11 24 50 36	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV. Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [2.68, 3.32] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Total (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at 6months Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Join 2009	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6	$ \begin{array}{r} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas) 0.52 \\ 0.4 \\ 0.6 \end{array}	28 11 62 < 0.00 004) sty <u>Total</u> 10 28 50	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5 2.6	0.6 1 = 97% oplas <u>SD</u> 0.67 0.7 0.6	24 15 67 ty <u>Total</u> 11 24 50	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% -0.15 [-0.66, 0.36] 3.00 [2.68, 3.32] 0.00 [-0.24, 0.24]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.5 at Growths Study or Subgroup De Negri 2207 Kumar 2010 Ju 2010 Jovi 2009 Santiago 2010	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas <u>SD</u> 0.52 0.4 0.6 2 \end{array}	28 11 62 < 0.000 004) sty Total 10 28 50 118 30	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6	0.6 1 = 97% ooplas <u>SD</u> 0.67 0.7 0.6 2	24 15 67 ty <u>Total</u> 11 24 50 36 30	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.5 at Growths Study or Subgroup De Negri 2207 Kumar 2010 Ju 2010 Jovi 2009 Santiago 2010	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $ = 2 (P (P = 0. broplas <u>SD</u> 0.52 0.4 0.6 2 \end{array}	28 11 62 < 0.00 004) sty Total 10 28 50 118	3.3 1.6 001); l ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6	0.6 1 = 97% ooplas <u>SD</u> 0.67 0.7 0.6 2	24 15 67 ty <u>Total</u> 11 24 50 36 30	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Vilat 2007 Total (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Jumar 2010 Jumar 2010 Jumar 2010 Jourd 2009 Santiago 2010 Total (95% CI)	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5	1 0.7 1 (P = 0. (P = 0. 0.52 0.4 0.6 2 2	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236	3.3 1.6 001); ² = kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2	24 15 67 ty Total 11 24 50 36 30 151	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV. Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [2.68, 3.32] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² =	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 2< 0.0	3.3 1.6 001); ² = kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); ²	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2	24 15 67 ty Total 11 24 50 36 30 151	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01]	-100 -50 0 50 1 avours experimental Favours control Mean Difference I. IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² =	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 2< 0.0	3.3 1.6 001); ² = kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); ²	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2	24 15 67 ty Total 11 24 50 36 30 151	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95%, Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect:	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.3;	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.0000	3.3 1.6 001); l ² = kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); l ²	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 := 98%	24 15 67 ty Total 11 24 50 36 30 36 30 151 6	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV. Fixed, 95% C1 -100 -50 0 50 1 Favours experimental Favours control
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect:	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.3;	$ \begin{array}{c} 1 \\ 0.7 \\ 1 \end{array} $	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.0000	3.3 1.6 001); l ² = kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); l ²	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2	24 15 67 ty Total 11 24 50 36 30 36 30 151 6	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95%, Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup Do Negri 2207 Kumar 2010 Liu 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.32 vertel	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.00000 sty	3.3 1.6 001); ² = kyph Mean 0.7 2.5 2.6 2.6 3.5 0001); ² 1) kyph	0.6 1 = 97% 0.67 0.6 2 2 2 = 98%	24 15 67 ty Total 11 24 50 36 30 151 %	64.6% 13.3% 100.0% 110.0% 11.1% 28.8% 52.2% 5.2% 2.8% 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV. Fixed, 95% C -0.15 [-0.66, 0.6] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Ideterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Jui 2010 Jovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup	5.6 3.1 1.4 64.34, df Z = 2.89 vertel Mean 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.32 vertel Mean	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 < 0.00 0.0000 sty Total	3.3 1.6 0001); I ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); I ² 1) kyph <u>Mean</u>	0.6 1 = 97% 0.07 0.6 2 2 = 98%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8% 100.0% <u>Weight</u>	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV. Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.16] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV. Fixed, 95% C	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% CI
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Ideterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Jui 2010 Jovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup	5.6 3.1 1.4 64.34, df Z = 2.89 vertel <u>Mean</u> 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.32 vertel	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 5 < 0.00 0.0000 sty Total 23	3.3 1.6 0001); I ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 2.6 3.5 3.5 00001); I ² 1) kyph <u>Mean</u> 2.7	0.6 1 = 97% 0.67 0.6 2 2 = 98% moplas <u>SD</u> 1	24 15 67 ty Total 11 24 50 36 30 151 %	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8% 100.0% <u>Weight</u> 9.4%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.63, 3.22] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% CI
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Forst for overall effect: 3.5 at Gmonths Study or Subgroup Study or Subgroup De Negri 2207 (umar 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005	5.6 3.1 1.4 64.34, df Z = 2.89 vertel Mean 0.55 5.5 2.6 3 4.5 243.02, d Z = 10.32 vertel Mean	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 < 0.00 0.0000 sty Total	3.3 1.6 0001); I ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); I ² 1) kyph <u>Mean</u>	0.6 1 = 97% 0.07 0.6 2 2 = 98%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 52.2% 5.2% 2.8% 100.0% <u>Weight</u>	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.63, 3.22] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% CI
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup De Negri 2207 (umar 2010 .iu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Stohs 2005 Movinin2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.0000 \$ sty Total 236 237	3.3 1.6 0001); I ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 3.5 00001); I ² 1) kyph <u>Mean</u> 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% 0.67 0.6 2 2 := 98% noplas <u>SD</u> 1 2	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 28 46	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 5.2% 2.8% 100.0% <u>Weight</u> 9.4% 3.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.35]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 (umar 2010 .iu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movinin2010 Pilat 2007	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.0000 \$ sty Total 23 27 11	3.3 1.6 0001); l ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 00001); l ² 1) kyph <u>Mean</u> 2.7 2 1.3	0.6 1 = 97% noplass <u>SD</u> 0.67 0.6 2 2 := 98% SD := 98% 1 2 2	24 15 67 ty Total 11 24 50 36 30 151 % ty Total 28 46 15	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 5.2% 2.8% 100.0% <u>Weight</u> 9.4% 3.2% 1.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV. Fixed, 95% C -0.15 [-0.60, 0.6] 3.00 [-0.8, 3.22] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV. Fixed, 95% C 3.00 [2.45, 3.55] -0.20 [-1.76, 1.36]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 (umar 2010 .iu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movinin2010 Pilat 2007	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.0000 \$ sty Total 236 237	3.3 1.6 0001); I ² : kyph <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 3.5 00001); I ² 1) kyph <u>Mean</u> 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% 0.67 0.6 2 2 := 98% noplas <u>SD</u> 1 2	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 28 46	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 5.2% 2.8% 100.0% <u>Weight</u> 9.4% 3.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.35]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths 3.5 at Gmonths 3.5 at Gmonths 3.6 at Orgenity Suday or Subgroup De Negri 2207 Kumar 2010 Jui 2010 Jovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Advirinz010 Pilat 2007 Santiago 2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 0 < 0.00 0.00000 sty Total 23 27 11 30	3.3 1.6 0001); I ² : kyph Mean 0.7 2.5 2.6 2.6 3.5 2.6 2.6 3.5 00001); I ² (Mean 2.7 2 1.3 3.7	0.6 1 = 97% noplas <u>SD</u> 0.6 2 2 2 = 98% SD 0.6 2 2 := 98% 1 2 2 2 2	24 15 67 Total 11 24 50 36 30 151 6 ty Total 8 ty Total 50 6 7 50 8 8 8 6 7 50 8 8 8 6 7 8 9 8 9 8 9 8 9 8 9 9 9 9 9 9 9 9 9 9	64.6% 13.3% 100.0% <u>Weight</u> 11.1% 28.8% 5.2% 2.8% 100.0% <u>Weight</u> 9.4% 3.2% 1.2%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.35] 0.40 [-0.51, 1.36] 0.40 [-0.51, 1.36] 0.40 [-0.51, 1.36] 0.40 [-0.51, 1.36] 0.40 [-0.51, 1.36] 0.40 [-0.51, 1.36]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Forst for overall effect: 3.5 at Gmonths Study or Subgroup Study or Subgroup Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Santiago 2010 Sons 2005 dovinin2010 Pilat 2007 Santiago 2010 Schofer 2009	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 6 2 < 0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.000 118 30 236 236 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 237 236 237 237 237 237 237 237 237 237 237 237	3.3 3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 2.0001); I ² : kypt <u>Mean</u> 2.7 2.1 3.3 7.2 6	0.6 1 = 97% opplas SD 0.67 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3	24 15 67 Total 11 24 50 36 30 151 6 ty Total 28 46 15 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 1.2% 2.8% 4.5%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.63, 3.22] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 0.30 [-0.59, 0.99]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.5 af Groorths Study or Subgroup Study or Subgroup Soniago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.6 at 1 year Study or Subgroup Srohs 2005 Avirin2010 Value 2010 Santiago 2010 Scholar 2005 Avirin2010 Value 2010 Santiago 2010 Scholar 2005 Avirin2010 Value 2010 Scholar 2009 Variantiago 2010 Scholar 2009 Yan 2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 50 0.00000 sty Total 23 27 11 30 30 94	3.3 1.6 kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); ² ² 2.6 3.5 0001); ² 10 kyph <u>Mean</u> 2.7 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% opplas SD 0.67 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3 0.51	24 15 67 Total 11 24 50 36 30 151 % ty Total 28 46 15 30 30 98	64.6% 13.3% 100.0% Weightt 52.2% 5.2% 2.8% 100.0% Weightt 9.4% 3.2% 1.2% 63.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.20 [-1.76, 1.36] 0.30 [-0.11, 1.91] 1.20 [-0.11, 1.91] 1.21 [-20, 0.69] 1.41 [1.20, 1.62]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.5 af Groorths Study or Subgroup Study or Subgroup Soniago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.6 at 1 year Study or Subgroup Srohs 2005 Avirin2010 Value 2010 Santiago 2010 Scholar 2005 Avirin2010 Value 2010 Santiago 2010 Scholar 2005 Avirin2010 Value 2010 Scholar 2009 Variantiago 2010 Scholar 2009 Yan 2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 6 2 < 0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.000 118 30 236 236 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 236 237 118 30 237 236 237 237 237 237 237 237 237 237 237 237	3.3 3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 2.0001); I ² : kypt <u>Mean</u> 2.7 2.1 3.3 7.2 6	0.6 1 = 97% opplas SD 0.67 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3	24 15 67 Total 11 24 50 36 30 151 6 ty Total 28 46 15 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 1.2% 2.8% 4.5%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.63, 3.22] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] F Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 0.30 [-0.59, 0.99]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Test for overall effect: 3.5 af Groonths Study or Subgroup De Negri 2207 Kumar 2010 iu 2010 ovi 2009 Santiago 2010 Total (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Sontiago 2010 Stody coust Stody or Subgroup Santiago 2010 Stody or Subgroup Sinchar 2005 Movinin2010 Pilat 2007 Santiago 2010 Schofer 2009 Yan 2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 50 0.00000 sty Total 23 27 11 30 30 94	3.3 1.6 kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); ² ² 2.6 3.5 0001); ² 10 kyph <u>Mean</u> 2.7 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% opplas SD 0.67 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3 0.51	24 15 67 Total 11 24 50 36 30 151 % ty Total 28 46 15 30 30 98	64.6% 13.3% 100.0% Weightt 52.2% 5.2% 2.8% 100.0% Weightt 9.4% 3.2% 1.2% 63.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.20 [-1.76, 1.36] 0.30 [-0.11, 1.91] 1.20 [-0.11, 1.91] 1.21 [-20, 0.69] 1.41 [1.20, 1.62]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Study or Subgroup Grohs 2005 Sinola 2005 Villat 2007 Fotal (95% CI) Feletorgeneity: Chi² = Fest for overall effect: 3.5 at 6months Study or Subgroup De Negri 2207 Kumar 2010 Lovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Groht 2005 Worvinto210 Pilat 2007 Santiago 2010 Schdy or Subgroup Schot 2005 Korror Subgroup Santiago 2010 Schot 2005 Yorin2010 Pilat 2007 Santiago 2010 Schot 2009 Schot 2009 Schot 2009 Schot 2009 Schot 2009 Chou 2008	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 0 < 0.00 0.00000 sty Total 23 27 11 30 30 94 56	3.3 1.6 kyph <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 0001); ² ² 2.6 3.5 0001); ² 10 kyph <u>Mean</u> 2.7 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.6 3.5 0001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% opplas SD 0.67 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3 0.51	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% 411.1% 28.8% 52.2% 2.8% 100.0% 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [245, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 1.00 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup Stat Groonths Study or Subgroup Sontago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movinin2010 Pilat 2007 Santiago 2010 Schot 1 year Study or Subgroup Sontago 2010 Schots 2005 Movinin2010 Pilat 2007 Santiago 2010 Schoter 2009 Yan 2010	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 0 < 0.00 0.00000 sty Total 23 27 11 30 30 94 56 271	3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); ² () kypt <u>Mean</u> 2.7 2.7 2.6 3.5 00001); ² () 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% Weightt 52.2% 5.2% 2.8% 100.0% Weightt 9.4% 3.2% 1.2% 63.8%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.20 [-1.76, 1.36] 0.30 [-0.11, 1.91] 1.20 [-0.11, 1.91] 1.21 [-20, 0.69] 1.41 [1.20, 1.62]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup Stat Groonths Study or Subgroup Sontago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movinin2010 Pilat 2007 Santiago 2010 Schotar 2009 Santiago 2010 Fortal (95% CI) Santago 2010 Schotar 2009 Santiago 2010 Schotar 2009 Santiago 2010 Schotar 2009 Yan 2010 Zhou 2008 </td <td>$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$</td> <td>$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$</td> <td>28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 0 < 0.00 0.00000 sty Total 23 27 11 30 30 94 56 271</td> <td>3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); ² () kypt <u>Mean</u> 2.7 2.7 2.6 3.5 00001); ² () 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7</td> <td>0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1</td> <td>24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30</td> <td>64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%</td> <td>-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [245, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 1.00 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53]</td> <td>-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl</td>	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \end{array}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 6 0 < 0.00 0.00000 sty Total 23 27 11 30 30 94 56 271	3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); ² () kypt <u>Mean</u> 2.7 2.7 2.6 3.5 00001); ² () 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.6 3.5 00001); ² 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [245, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 1.00 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Grohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at Gronorths Study or Subgroup De Negri 2207 Kumar 2010 iu 2010 ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Sonbar 2005 Movinin2010 Pilat 2007 Santiago 2010 Schofer 2005 Movinin2010 Sintiago 2010 Schofer 2009 (an 2010 Zhou 2008 Fotal (95% CI) Heterogeneity: Chi² =	5.6 3.1 1.4 64.34, df 4 64.34, df 4 64.34, df 4 7 2.89 0.65 5.5 2.6 3 3 4.5 243.02, d 7 243.02, d 7 243.02, d 8 1.36, df 4 81.36, df 4 81.	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 30 236 0 < 0.0000 0.00000 sty Total 23 27 11 30 30 94 56 271 < 0.000	3.3 3.3 1.6 kypH Mean 0.7 2.5 2.6 2.6 2.6 2.6 3.5 00001); ² = () kypH Mean 2.7 2.5 2.6 2.6 3.5 00001; ² = () () () () () () () () () ()	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [245, 3.55] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 1.00 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.5 af Groonths Study or Subgroup De Negri 2207 Kumar 2010 .iu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 8.6 at 1 year Study or Subgroup Jorohs 2005 Advirin2010 Pilat 2007 Santiago 2010 Schudy or Subgroup Schoder 2005 Aovinin2010 Pilat 2007 Santiago 2010 Schuder 2009 (an 2010 Zhou 2008 Fotal (95% CI) Heterogeneity: Chi² =	5.6 3.1 1.4 64.34, df 4 64.34, df 4 64.34, df 4 7 2.89 0.65 5.5 2.6 3 3 4.5 243.02, d 7 243.02, d 7 243.02, d 8 1.36, df 4 81.36, df 4 81.	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 30 236 0 < 0.0000 0.00000 sty Total 23 27 11 30 30 94 56 271 < 0.000	3.3 3.3 1.6 kypH Mean 0.7 2.5 2.6 2.6 2.6 2.6 3.5 00001); ² = () kypH Mean 2.7 2.5 2.6 2.6 3.5 00001; ² = () () () () () () () () () ()	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.42, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.58, 0.99] 1.41 [1.20, 162] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup Sonta Groot Subgroup Jona Polygin 2207 Kumar 2010 Jui 2010 Jovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: Study or Subgroup Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Santiago 2010 Schofer 2009 Jantiago 2010 Schofer 2009 (an 2016) Schofer 2009 (an 2016) (an 2016) <td>5.6 3.1 1.4 64.34, df 4 64.34, df 4 64.34, df 4 7 2.89 0.65 5.5 2.6 3 3 4.5 243.02, d 7 243.02, d 7 243.02, d 8 1.36, df 4 81.36, df 4 81.</td> <td>$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$</td> <td>28 11 62 < 0.000 004) sty Total 28 50 118 30 236 0 < 0.0000 0.00000 sty Total 23 27 11 30 30 94 56 271 < 0.000</td> <td>3.3 3.3 1.6 kypH Mean 0.7 2.5 2.6 2.6 2.6 2.6 3.5 00001); ² = () kypH Mean 2.7 2.5 2.6 2.6 3.5 00001; ² = () () () () () () () () () ()</td> <td>0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1</td> <td>24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30</td> <td>64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%</td> <td>-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.42, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.58, 0.99] 1.41 [1.20, 162] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41]</td> <td>-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Favours experimental Favours control</td>	5.6 3.1 1.4 64.34, df 4 64.34, df 4 64.34, df 4 7 2.89 0.65 5.5 2.6 3 3 4.5 243.02, d 7 243.02, d 7 243.02, d 8 1.36, df 4 81.36, df 4 81.	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 30 236 0 < 0.0000 0.00000 sty Total 23 27 11 30 30 94 56 271 < 0.000	3.3 3.3 1.6 kypH Mean 0.7 2.5 2.6 2.6 2.6 2.6 3.5 00001); ² = () kypH Mean 2.7 2.5 2.6 2.6 3.5 00001; ² = () () () () () () () () () ()	0.6 1 = 97% noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% <u>SD</u> 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 % ty Total 50 (151) % 151 50 30 30 30 30 30 30 30 30	64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.42, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.58, 0.99] 1.41 [1.20, 162] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Favours experimental Favours control
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup Sonta Constraints Study or Subgroup Sontago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Sontiago 2010 Fotal (95% CI) Bilat 2007 Jantiago 2010 Schofer 2005 Jovirin2010 Santiago 2010 Schofer 2009 Yan 2010	5.6 3.1 1.4 64.34, df $Z = 2.89$ vertel Mean 0.55 5.5 2.6 3.5 243.02, d, 4.5 243.02, d, 57 243.02, d, 57 243.02, d, 57 243.02, d, 67 81.36, df $Z = 14.35$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 118 30 236 60 < 0.00 0.0000 sty Total 23 27 11 30 30 94 56 271 < 0.00 0.000	3.3 1.6 kyph Mean 0.7 2.5 2.6 2.6 2.6 3.5 00001); I ² 1) kyph Mean 2.7 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24 2.6 1.24	0.6 1 = 97% 0.07 0.7 0.7 0.6 2 2 2 = 98% SD 1 2 2 2 1.3 0.51 1	24 15 67 Total 11 24 50 36 30 151 6 * ty Total 28 46 5 30 30 98 32 279	64.6% 13.3% 100.0% Weight 11.1% 28.8% 52.2% 2.8% 100.0% Weight 9.4% 3.2% 4.5% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.42, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.55, 1.35] 0.40 [-0.58, 0.99] 1.41 [1.20, 162] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Grnonths Study or Subgroup De Negri 2207 (umar 2010 .iu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Stohofsr 2005 Movinin2010 Pilat 2007 Santiago 2010 Schofer 2009 (an 2010 Chou 2008 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \hline \\ 64.34, df\\ Z = 2.89\\ \hline \\ wertel\\ \hline \\ Mean\\ 0.55\\ 5.5\\ 2.6\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 2\\ -10.3\\ \hline \\ 81.36, df\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 23 0.0000 0.0000 30 30 94 56 271 30 30 94 56 271 30 30 94 56	3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); ² 1) kypt <u>Mean</u> 2.7 2.1 3.7 2.5 2.6 2.6 2.6 3.5 00001); ² 4 2.5 2.6 2.6 2.6 2.6 2.6 3.5 00001); ² 4 2.5 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6	0.6 1 = 97% moplas SD 0.67 0.7 0.6 2 2 2 2 moplas SD 1 2 2 2 1 3 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 3 0.51 1 1 2 2 2 2 1.3 0.51 1 1 1 2 2 2 2 2 2 3 0.51 1 1 1 1 1 1 1	24 15 67 Total 11 24 50 30 151 6 ty Total 28 46 15 30 30 8 32 279 279	64.6% 13.3% 100.0% Weight 52.2% 5.2% 2.8% 100.0% Weight 1.2% 2.8% 1.2% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.36] 0.20 [-1.76, 1.36] 0.20 [-1.76, 1.36] 0.20 [-1.11, 1.31] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] Mean Difference	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 jui 2010 jui 2010 jowi 2009 Santiago 2010 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Brohs 2005 Adovinin2010 Pilat 2007 Santiago 2010 Schoft 2009 Yan 2010 Zhan 2010 Chou 2008 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years Study or Subgroup	5.6 3.1 1.4 4.34 , df $Z = 2.89$ vertel Wertel Wertel Wertel 1 2 2 3 4 .5 5.5 2 6 3 3 4 .5 243.02 , d 7 2 4 .5 243.02 , d 7 1 1 4 .6 2.88 2 2 2 3 3 4 .5 5.5 2 6 3 3 4 .5 5.5 2 6 6 3 3 4 .5 5.5 2 6 6 3 3 4 .5 5.5 2 6 6 7 7 7 1 1 4 6 6 2 .88 9 1 1 1 4 6 2 8 2 1 1 1 1 4 6 2 8 2 .65 5.7 2 7 7 1 1 1 1 4 6 2 .88 2 .65 5.7 2 .77 2 .47 1 1 1 1 1 1 1 1	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 2 < 0.000 0.00000 sty Total 23 27 11 30 0 94 56 271 4 50 271 1 30 277 11 30 277 11 30 277 11 30 277 11 30 277 11 30 30 30 30 30 30 30 30 30 30 30 30 30	3.3 1.6 kypł <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 0001); l ² = 1) kypł <u>Mean</u> 2.7 2.5 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6	0.6 1 = 97% 0.67 0.7 0.6 2 2 2 = 98% 1 1 2 2 2 1.3 0.51 1 = 93%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 8 46 15 30 30 8 8 32 279 279	64.6% 13.3% 100.0% Weight 11.1% 52.2% 5.2% 2.8% 100.0% Weight 100.0% Weight 100.0% Weight	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.6, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 0.40 [-0.53, 0.53] -0.20 [-1.7, 1.36] 0.90 [-0.11, 1.91] 0.20 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] F Mean Difference IV, Fixed, 95% C	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 jui 2010 jui 2010 jowi 2009 Santiago 2010 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Brohs 2005 Adovinin2010 Pilat 2007 Santiago 2010 Schoft 2009 Yan 2010 Zhan 2010 Chou 2008 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years Study or Subgroup	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \hline \\ 64.34, df\\ Z = 2.89\\ \hline \\ wertel\\ \hline \\ Mean\\ 0.55\\ 5.5\\ 2.6\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ 2\\ -10.3\\ \hline \\ 81.36, df\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.1\\ 1.$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.00 004) sty Total 10 28 50 23 0.0000 0.0000 30 30 94 56 271 30 30 94 56 271 30 30 94 56	3.3 1.6 kypt <u>Mean</u> 0.7 2.5 2.6 2.6 3.5 00001); ² 1) kypt <u>Mean</u> 2.7 2.1 3.7 2.5 2.6 2.6 2.6 3.5 00001); ² 4 2.5 2.6 2.6 2.6 2.6 2.6 3.5 00001); ² 4 2.5 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6	0.6 1 = 97% moplas SD 0.67 0.7 0.6 2 2 2 2 moplas SD 1 2 2 2 1 3 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 3 0.51 1 1 2 2 2 2 1.3 0.51 1 1 1 2 2 2 2 2 2 3 0.51 1 1 1 1 1 1 1	24 15 67 Total 11 24 50 30 151 6 ty Total 28 46 15 30 30 8 32 279 279	64.6% 13.3% 100.0% Weight 52.2% 5.2% 2.8% 100.0% Weight 1.2% 2.8% 1.2% 63.8% 15.1%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 3.55] 0.40 [-0.55, 1.36] 0.20 [-1.76, 1.36] 0.20 [-1.76, 1.36] 0.20 [-1.11, 1.31] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] Mean Difference	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1 -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% C1
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lowi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Advirinz010 Pilat 2007 Santiago 2010 Schofer 2009 Yan 2010 Yohou 2008 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.7 at 2 years Study or Subgroup Grohs 2005	5.6 $(3, 1, 1, 4)$ 64.34, df $Z = 2.89$ vertel Mean 0.55 5.5 2.6 $(3, 3, 4, 5)$ 243.02, d, 4.5 2 243.02, d, 4.5 2	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 50 118 20 236 6 2 < 0.000 0.0000 sty Total 30 94 56 271 11 30 30 94 56 270 00 56 270 00 94 56 270 00 94 56 270 10 10 20 56 20 00 00 10 20 20 20 00 00 10 20 20 20 20 20 20 20 20 20 20 20 20 20	3.3 1.6 kyph 0.7 2.5 2.6 2.6 2.6 2.6 3.5 0001); I ² = () kyph Mean 2.7 2.6 1.24 2.6 0.7 2.5 0001); I ² = () kyph Mean 2.7 2.6 0.7 2.5 0.0 0.7 1.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 0.0 0.7 2.5 2.6 0.7 2.5 0.0 0.7 1.5 0.7 0.7 2.5 0.0 0.7 1.5 0.0 0.7 2.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.2 0.6 0.7 2.5 0.0 0.7 1.2 0.5 0.7 0.7 2.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	0.6 1 noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% 1 2 2 2 1.3 0.51 1 1 = 93%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 28 46 15 30 30 98 32 32 279 279	64.6% 13.3% 100.0% Weight 101.1% 28.8% 52.2% 2.8% 100.0% Weight 100.0% Weight 100.0% Weight 100.0% Weight 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 355] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 0.30 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] F Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lowi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Advirinz010 Pilat 2007 Santiago 2010 Schofer 2009 Yan 2010 Yohou 2008 Fotal (95% CI) Heterogeneity: Chi² = Fest for overall effect: 3.7 at 2 years Study or Subgroup Grohs 2005	5.6 3.1 1.4 4.34 , df $Z = 2.89$ vertel Wertel Main Sector 243.02 , d 243.02 , d 243.02 , d 243.02 , d 3 4.5 243.02 , d 7 243.02 , d 7 1 1 4.6 2 2 2 1 1 1 4.6 2 2 3 2 2 1 1 1 4.6 2 1 1 1 1 1 1 1 1	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 2 < 0.000 0.00000 sty Total 23 27 11 30 0 94 56 271 4 50 271 1 30 277 11 30 277 11 30 277 11 30 277 11 30 277 11 30 30 30 30 30 30 30 30 30 30 30 30 30	3.3 1.6 kypł <u>Mean</u> 0.7 2.5 2.6 2.6 2.6 3.5 0001); l ² = 1) kypł <u>Mean</u> 2.7 2.5 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6	0.6 1 = 97% 0.67 0.7 0.6 2 2 2 = 98% 1 1 2 2 2 1.3 0.51 1 = 93%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 8 46 15 30 30 8 8 32 279 279	64.6% 13.3% 100.0% Weight 11.1% 52.2% 5.2% 2.8% 100.0% Weight 100.0% Weight 100.0% Weight	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 355] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 0.30 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] F Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Grnonths Study or Subgroup De Negri 2207 (umar 2010 .uu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movirin2010 Pilat 2007 Santiago 2010 Schofer 2009 (an 2010 Chou 2008 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years Study or Subgroup Srohs 2005 .ovi 2009	5.6 $(3, 1, 1, 4)$ 64.34, df $Z = 2.89$ vertel Mean 0.55 5.5 2.6 $(3, 5, 5)$ 243.02, $(4, 5)$ 24	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.00 004) sty Total 28 50 118 30 236 6 < 0.00 0.0000 5 sty Total 23 27 11 30 94 56 < 271 < 0.000 0.0000 sty Total 23 30 94 56 50 118 217 118 217 217 217 217 217 217 217 217 217 217	3.3 1.6 kyph 0.7 2.5 2.6 2.6 2.6 2.6 3.5 0001); I ² = () kyph Mean 2.7 2.6 1.24 2.6 0.7 2.5 0001); I ² = () kyph Mean 2.7 2.6 0.7 2.5 0.0 0.7 1.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 0.0 0.7 2.5 2.6 0.7 2.5 0.0 0.7 1.5 0.7 0.7 2.5 0.0 0.7 1.5 0.0 0.7 2.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.2 0.6 0.7 2.5 0.0 0.7 1.2 0.5 0.7 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 0.7 2.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	0.6 1 noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% 1 2 2 2 1.3 0.51 1 1 = 93%	24 15 67 ty Total 24 50 36 30 151 4 50 30 151 5 4 6 ty Total 28 30 98 32 279 279 5 ty Total 28 36 30 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	64.6% 13.3% 100.0% Weightt 28.8% 52.2% 5.2% 2.8% 100.0% Weightt 1.2% 63.8% 15.1% 100.0% Weightt 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 0.00 [-1.1, 1.9] 0.30 [-1.76, 1.36] 0.30 [-1.1, 6.2] 0.10 [-0.3, 0.53] 1.24 [1.07, 1.41] Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59] 0.10 [-0.65, 0.85]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 (umar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Grnonths Study or Subgroup De Negri 2207 (umar 2010 .uu 2010 .ovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Movirin2010 Pilat 2007 Santiago 2010 Schofer 2009 (an 2010 Chou 2008 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years Study or Subgroup Srohs 2005 .ovi 2009	5.6 $(3, 1, 1, 4)$ 64.34, df $Z = 2.89$ vertel Mean 0.55 5.5 2.6 $(3, 5, 5)$ 243.02, $(4, 5)$ 24	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 50 118 20 236 6 2 < 0.000 0.0000 sty Total 30 94 56 271 11 30 30 94 56 270 04 56 270 04 20 56 270 10 20 20 56 20 20 20 56 20 20 20 20 20 20 20 20 20 20 20 20 20	3.3 1.6 kyph 0.7 2.5 2.6 2.6 2.6 2.6 3.5 0001); I ² = () kyph Mean 2.7 2.6 1.24 2.6 0.7 2.5 0001); I ² = () kyph Mean 2.7 2.6 0.7 2.5 0.0 0.7 1.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 2.6 0.7 2.5 0.0 0.7 2.5 2.6 0.7 2.5 0.0 0.7 1.5 0.7 0.7 2.5 0.0 0.7 1.5 0.0 0.7 2.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.5 0.0 0.7 1.2 0.6 0.7 2.5 0.0 0.7 1.2 0.5 0.7 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 2.6 0.7 0.7 2.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	0.6 1 noplas <u>SD</u> 0.67 0.7 0.6 2 2 2 = 98% 1 2 2 2 1.3 0.51 1 1 = 93%	24 15 67 ty Total 11 24 50 36 30 151 6 ty Total 28 46 15 30 30 98 32 32 279 279	64.6% 13.3% 100.0% Weight 101.1% 28.8% 52.2% 2.8% 100.0% Weight 100.0% Weight 100.0% Weight 100.0% Weight 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 3.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 3.00 [2.45, 355] 0.40 [-0.55, 1.35] -0.20 [-1.76, 1.36] 0.30 [-0.59, 0.99] 1.41 [1.20, 1.62] 0.10 [-0.33, 0.53] 1.24 [1.07, 1.41] F Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.5 at Gmonths Study or Subgroup De Negri 2207 Kumar 2010 Liu 2010 Lowi 2009 Santiago 2010 Fotal (95% CI) Ideterogeneity: Chi ² = Fest for overall effect: 3.6 at 1 year Study or Subgroup Srohs 2005 Aovinin2010 Pilat 2007 Santiago 2010 Chol (95% CI) Heterogeneity: Chi ² = Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.7 at 2 years Study or Subgroup Grohs 2005 Lowi 2009 Fotal (95% CI) Heterogeneity: Chi ² = Fotal 2005 Lowi 2009 Fotal 2005 Lowi 2009 Study or Subgroup Study or Subgroup Study	$\begin{array}{c} 5.6\\ 3.1\\ 1.4\\ \hline \\ 64.34, df\\ Z = 2.89\\ \hline \\ \text{Wean}\\ 0.55\\ 5.5\\ 2.6.\\ 3\\ 4.5\\ \hline \\ 243.02, d\\ 4.5\\ \hline \\ 243.02, d\\ 3\\ Z = 10.33\\ \hline \\ \text{wertel}\\ \hline \\ \hline \\ \text{Mean}\\ 1.1\\ 4.6\\ 2.8\\ 2.65\\ \hline \\ 2.7\\ \hline \\ 81.36, df\\ Z = 14.33\\ \hline \\ \text{wertel}\\ \hline \\ \text{Mean}\\ 4.6\\ 2\\ \hline \\ 2\\ \end{bmatrix}$	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 10 28 50 118 30 236 2 < 0.000 0.00000 sty Total 23 27 11 30 0 94 56 271 (0.000 0.0000 50 51 271 13 30 271 13 30 271 13 30 30 30 30 30 30 30 30 30 30 30 30 30	3.3 3.3 1.6 kypł Mean 0.7 2.5 2.6 2.6 3.5 2.6 2.6 3.5 2.6 1.5 2.5 2.6 1.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2	0.6 1 moplas <u>SD</u> 0.67 0.7 0.6 2 2 2 3 SD 1 2 2 2 1.3 0.51 1 1 = 93% moplas <u>SD</u> 1.5 2 2 2 2 1.5 2 2 2 2 2 2 2 2 2 2 2 2 2	24 15 67 ty Total 24 50 36 30 151 4 50 30 151 5 4 6 ty Total 28 30 98 32 279 279 5 ty Total 28 36 30 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	64.6% 13.3% 100.0% Weightt 28.8% 52.2% 5.2% 2.8% 100.0% Weightt 1.2% 63.8% 15.1% 100.0% Weightt 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 0.00 [-1.1, 1.9] 0.30 [-1.76, 1.36] 0.30 [-1.1, 6.2] 0.10 [-0.3, 0.53] 1.24 [1.07, 1.41] Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59] 0.10 [-0.65, 0.85]	-100 -50 0 50 11 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Tavours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 11 Favours control Mean Difference 2 IV, Fixed, 95% Cl
Srohs 2005 Kumar 2010 Pilat 2007 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: 3.5 at Groonths Study or Subgroup Sonta Groot Subgroup Jona Polygin 2207 Kumar 2010 Jui 2010 Jovi 2009 Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Fest for overall effect: Study or Subgroup Santiago 2010 Fotal (95% CI) Heterogeneity: Chi ² = Santiago 2010 Schofer 2009 Jantiago 2010 Schofer 2009 (an 2016) Schofer 2009 (an 2016) (b) Schofer 2	5.6 3.1 1.4 64.34, df Z = 2.89 vertel Mean 0.55 5.5 243.02, d, 4.5 243.02, d, 4.5 243.02, d, 4.5 243.02, d, 4.5 245.02, d, 4.5 245.02, d, 4.5 245.02, d, 4.5	$\begin{array}{c} 1 \\ 0.7 \\ 1 \\ \end{array}$	28 11 62 < 0.000 004) sty Total 28 50 118 50 118 20 20 6 2 30 20 6 2 30 20 5 2 30 20 5 4 5 6 2 7 11 30 30 94 56 2 71 1 30 30 94 56 2 71 1 2 3 118 23 60 00 00 94 56 2 30 000 00 94 56 2 30 20 60 94 10 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 60 20 20 20 60 20 20 20 20 20 20 20 20 20 20 20 20 20	3.3 3.3 1.6 kypł Mean 0.7 2.5 2.6 2.6 3.5 2.6 2.6 3.5 2.6 1.5 2.5 2.6 1.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2	0.6 1 moplas <u>SD</u> 0.67 0.7 0.6 2 2 2 3 SD 1 2 2 2 1.3 0.51 1 1 = 93% moplas <u>SD</u> 1.5 2 2 2 2 1.5 2 2 2 2 2 2 2 2 2 2 2 2 2	24 15 67 ty Total 24 50 36 30 151 4 50 30 151 5 4 6 ty Total 28 30 98 32 279 279 5 ty Total 28 36 30 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	64.6% 13.3% 100.0% Weightt 28.8% 52.2% 5.2% 2.8% 100.0% Weightt 1.2% 63.8% 15.1% 100.0% Weightt 100.0%	-0.20 [-0.55, 0.15] -0.20 [-0.98, 0.58] 0.42 [0.14, 0.70] Mean Difference IV, Fixed, 95% C -0.15 [-0.66, 0.36] 0.00 [-0.24, 0.24] 0.40 [-0.35, 1.15] 1.00 [-0.01, 2.01] 0.89 [0.72, 1.06] Mean Difference IV, Fixed, 95% C 0.00 [-1.1, 1.9] 0.30 [-1.76, 1.36] 0.30 [-1.1, 6.2] 0.10 [-0.3, 0.53] 1.24 [1.07, 1.41] Mean Difference IV, Fixed, 95% C 2.60 [1.61, 3.59] 0.10 [-0.65, 0.85]	-100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl -100 -50 0 50 1 Favours experimental Favours control Mean Difference 1 IV, Fixed, 95% Cl

Fig. 1. The forest plots of meta-analysis of VAS score.

 Table 4

 Results of meta-analysis of clinical outcome measures

Outcomes or subgroups	No. of studies	No. of patients	Statistical method	Effect estimate (95% CI) [†]	P value
(3) VAS score					
3.1 Baseline	11	877	WMD	0.14 [-0.01, 0.28]	>.05
3.2 at 1–7days	6	362	WMD	0.18 [0.02, 0.34]	<.05*
3.3 at 1 month	2	214	WMD	0.45 [0.15, 0.75]	<.05*
3.4 at 3 months	3	129	WMD	0.42 [0.14, 0.70]	<.05*
3.5 at 6 months	5	387	WMD	0.89 [0.72, 1.06]	<.05*
3.6 at 1 year	7	550	WMD	1.24 [1.07, 1.41]	<.05*
3.7 at 2 years	2	205	WMD	1.01 [0.41, 1.60]	<.05*
(4) ODI					
4.1 Baseline	5	338	WMD	3.56 [1.61, 5.51]	<.05*
4.2 at 1 week	1	52	WMD	10.40 [8.06, 12.74]	<.05*
4.3 at 1 month	2	214	WMD	2.82 [0.72, 4.91]	<.05*
4.4 at 3 months	3	257	WMD	4.31 [1.95, 6.67]	<.05*
4.5 at 6 months	3	235	WMD	0.45 [-0.82, 1.72]	>.05
4.7 at 1 year	2	111	WMD	4.43 [-1.27, 10.13]	<.05*
4.8 At 2 years	2	205	WMD	-4.00 [-11.57, 3.57]	>.05
(5) EQ-5D					
5.1 Baseline	1	52	WMD	-0.08 [-0.12, -0.03]	<.05*
5.3 at 1 week	1	52	WMD	-0.37 [-0.41, -0.33]	<.05*
5.4 at 3 months	1	52	WMD	-0.15 [-0.18 , -0.12]	<.05*
5.5 at 10 months	1	52	WMD	-0.24 [-0.28 , -0.21]	<.05*

WMD, indicated weighted mean difference; CI, confidence interval.

If effect estimate is positive (>0), it means vertebroplasty group is more than kyphoplasty group. If it is negative (<0), it means vertebroplasty group is less than kyphoplasty group. Whether it is significant lies on the *P* value.

*Statistically significant.

[†]Effect estimate.

even 2 years after operation, the VAS score in the vertebroplasty group was significantly more than the kyphoplasty group. These results mean that pain relief after kyphoplasty is significantly greater than that achieved with vertebroplasty. The benefits can be sustained for at least 2 years. The vertebral height and kyphosis angle for the vertebroplasty group was similar to the kyphoplasty group at baseline, but after operation, the vertebral height was significantly less and the kyphosis angle was significantly more than the kyphoplasty group. The improvement in the

6.1 baseline	Verte	ebropla	sty	Ky	phopla	asty		Mean Difference	e Mea	n Difference	
Study or Subgroup	Mean	SD	Total	Mean	S) Tota	al Weigh	nt IV, Fixed, 95%	CI IV, F	ixed, 95% CI	
Movirin2010	55.5	8.2	27	59.4	12.5	5 4	6 36.69	% -3.90 [-8.66, 0.8	6]	-	
Yan 2010	53.46	11.28	94	52.23	14.1	5 9	8 63.49	% 1.23 [-2.38, 4.8	4]	•	
Total (95% CI)			121			14	4 100.0	% -0.65 [-3.52, 2.23	3]	•	
Heterogeneity: Chi ² =	2.83, df	= 1 (P =	0.09);	² = 65 ⁰	%				400 50		400
Test for overall effect:	Z = 0.44	(P = 0.	66)						-100 -50	0 50	100
6.2 mont amounts		` 		14				N	Favours experimer		uoi
6.2 post-operativ		•			hoplas		W:	Mean Difference		an Difference	
Study or Subgroup	Mean		Total				Weight	IV, Fixed, 95%		Fixed, 95% Cl	
Movirin2010	65	7.9	27	81.1	10.6	46		-16.10 [-20.37, -11.	- 1	<u>.</u>	
Yan 2010	64.55	12.47	94	83.86	16.72	98	51.3%	-19.31 [-23.47, -15.	15]	-	
Total (95% CI)			121			144	100.0%	-17.75 [-20.73, -14.3	77]	•	
Heterogeneity: Chi ² = 1	I.11, df =	1 (P = (0.29); l ²	= 10%							
Test for overall effect: 2	Z = 11.67	(P < 0.	00001)						-100 -50	0 50 ntal Favours.cor	10 trol
									Favours experime	nial Favours cor	ILI OI
6.3 improveme	nt Verte	bropla	sty	Кур	hoplas	sty		Mean Difference	Mea	n Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI IV,	Fixed, 95% CI	
Grohs 2005	0.5	0.5	23	5.8	4	28	64.2%	-5.30 [-6.80, -3.8	30]		
Movirin2010	9.5	6.2	27	21.7	12.4	46	7.8%	-12.20 [-16.48, -7.9	92]	-	
Yan 2010	11.13	5.68	94	21.46	9.87	98	28.0%	-10.33 [-12.60, -8.0	06]	•	
								•			
Total (95% CI)			144			172	100.0%	-7.25 [-8.45, -6.0	5]	1	
Heterogeneity: Chi ² =	18.76, df	= 2 (P	< 0.000	1); ² =	89%				-100 -50	0 50	10
										0 50	10

Fig. 2. The forest plots of meta-analysis of vertebral height.

8.1 baseline	Verte	bropla	sty	Kyp	hoplas	sty		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV. Fixed, 95% CI
Liu 2010	15.5	4.2	50	17	7.3	50	17.3%	-1.50 [-3.83, 0.83]	+
Movirin2010	11.3	4.2	27	11.8	5.5	51	19.7%	-0.50 [-2.69, 1.69]	+
Schofer 2009	11.4	3.4	30	12.5	2.8	30	37.9%	-1.10 [-2.68, 0.48]	•
Yan 2010	17.53	5.28	94	18.47	8.16	98	25.1%	-0.94 [-2.88, 1.00]	•
Total (95% CI)			201			229	100.0%	-1.01 [-1.98, -0.04]	
Heterogeneity: Chi ² =	0.40, df =	3 (P =	0.94);	² = 0%					
Test for overall effect:	Z = 2.04	(P = 0.	04)					-	-100 -50 0 50 100 avours experimental Favours control
0.0									'
8.2 post-operativ					hopla			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean			Weight		I IV, Fixed, 95% CI
Liu 2010	12.2	3.6	50	9	5.7	50			
Movirin2010	8.9	4.5	27	4.1	3.7	51			
Schofer 2009	9.3	3.1	30	6.6	2.4	30			
Yan 2010	12.67	3.46	94	7.27	4.32	98	43.8%	5.40 [4.30, 6.50]	-
Total (95% CI)			201			229	100.0%	4.25 [3.52, 4.98]	ł
Heterogeneity: Chi ² =	10.36, df	= 3 (P	= 0.02); ² = 71	۱%				
Test for overall effect:	Z = 11.3	8 (P < 1	0.0000	1)				-	-100 -50 0 50 100 avours experimental Favours control
8.3 improveme		bropla	ct.	Kun	hoplas			Mean Difference	Mean Difference
_Study or Subgroup	Mean	•	-	Mean	•		Weight		
Grohs 2005	0.5	0.5	23	<u>iviean</u> 6	30	28	17.8%	-5.50 [-6.63, -4.37]	
Movirin2010	2.3	2.3	23	7.7	4.5	20 51	10.0%	-5.40 [-6.91, -3.89]	-
Pflugmacher 2005	2.5	2.5	32	7	4 .5 2	35	40.7%	-6.00 [-6.75, -5.25]	
Schofer 2009	2	2.4	30	5.9	2.7	30	13.6%	-3.90 [-5.19, -2.61]	
Yan 2010	5.21	2.33	94	11.69	5.18	98	17.9%	-6.48 [-7.61, -5.35]	
14112010	0.21	2.00	04	11.00	0.10	00	11.070	0.40[1.01, 0.00]	
Total (95% CI)			206			242	100.0%	-5.65 [-6.13, -5.17]	4
Heterogeneity: Chi ² =	10.13, df	= 4 (P	= 0.04)	; l² = 61	%				-100 -50 0 50 100
Test for overall effect:	Z = 23.23	2 (P < 0).00001)				F	avours experimental Favours control
								ſ	

Fig. 3. The forest plots of meta-analysis of kyphosis angle.

To avoid selection bias, we searched MEDLINE, EMBASE, Web of knowledge, Sciencedirect, EBSCO,

Springlink, Scopus, the Cochrane library, and any other

database that may possibly contain useful studies for relevant

articles in this meta-analysis. Moreover, all reference lists were

checked manually. Only "vertebroplasty" or "kyphoplasty" were selected as keywords and no language restrictions were

applied. In this way, we avoided losing any useful studies

vertebral height and kyphosis angle for the vertebroplasty group was significantly less than the kyphoplasty group. As for complications, the adjacent new vertebral fractures were similar in both groups at 6 months and 1 year after operation. The cement leakage to disc, paravertebral cement leakage, and the total cement leakage for the vertebroplasty group were all significantly more than the kyphoplasty group.

Table 5

Results of	meta-analysis	of radiological	outcome measures
------------	---------------	-----------------	------------------

Outcomes or subgroups	No. of studies	No. of patients	Statistical method	Effect estimate (95% CI) [†]	P value
(6) Vertebral height (%)					
6.1 Baseline	2	265	WMD	-0.65 [-3.52, 2.23]	>.05
6.2 Postoperative	2	265	WMD	-17.75 [-20.73, -14.77]	<.05*
6.3 Improvement	3	316	WMD	-7.25 [-8.45, -6.05]	<.05*
(7) Vertebral height (mm)					
7.1 Baseline	4	480	WMD	0.06 [-0.22, 0.33]	>.05
7.2 Postoperative	4	480	WMD	-2.38 [-2.67, -2.08]	<.05*
7.3 Improvement	2	248	WMD	-2.00 [-2.75, -1.25]	<.05*
(8) Kyphosis angle					
8.1 Baseline	4	430	WMD	-1.01 [-1.98, -0.04]	>.05
8.2 Postoperative	4	430	WMD	4.25 [3.52, 4.98]	<.05*
8.3 Improvement	5	448	WMD	-5.65 [-6.13, -5.17]	<.05*

WMD, indicated weighted mean difference; CI, confidence interval.

If effect estimate is positive (>0), it means vertebroplasty group is more than kyphoplasty group. If it is negative (<0), it means vertebroplasty group is less than kyphoplasty group. Whether it is significant lies on the P value.

*Statistically significant.

[†]Effect estimate.

	Vertebrop	lastv	Conservative trea	atment		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl	
27.3.2 at 6 months								
Frankel 2007	0	19	3	17	18.9%	0.11 [0.01, 2.22]	▲	
Liu 2010	0	50	2	50	13.0%	0.19 [0.01, 4.10]	·	
Subtotal (95% CI)		69		67	31.8%	0.14 [0.02, 1.21]		
Total events	0		5					
Heterogeneity: Chi ² = I	0.07, df = 1 (P = 0.79); I ² = 0%					
Test for overall effect:	Z = 1.78 (P =	= 0.07)						
27.3.3 at 1year								
Kumar 2010	2	28	1	24	5.2%	1.77 [0.15, 20.82]		
Lovi 2009	2	118	0	36	3.9%	1.57 [0.07, 33.38]		
Movirin2010	2	27	3	46	10.8%	1.15 [0.18, 7.34]		
Schofer 2009	1	30	0	30	2.5%	3.10 [0.12, 79.23]		
Yan 2010	18	94	11	98	45.7%	1.87 [0.83, 4.21]	+	
Subtotal (95% CI)		297		234	68.2%	1.78 [0.91, 3.49]		
Total events	25		15					
Heterogeneity: Chi ² = I	0.35, df = 4 (P = 0.99); I² = 0%					
Test for overall effect:	Z= 1.67 (P =	= 0.09)						
Total (95% CI)		366		301	100.0%	1.26 [0.69, 2.29]	+	
Total events	25		20					
Heterogeneity: Chi ² = !	5.32, df = 6 (P = 0.50); I ² = 0%					100
Test for overall effect:	Z = 0.75 (P =	= 0.46)				c	0.01 0.1 1 10 avours experimental Favours control	
Test for subaroup diffe	rences: Not	applicab	le			r	avours experimental Pavours control	1

Fig. 4. The forest plots of meta-analysis of adjacent new vertebral fractures.

even it lead to more ineligible studies received and more work. Because the first study about vertebroplasty was published at 1987, we searched the studies from January 1987 to July 2011. Reviewers independently selected articles on the basis of the inclusion criteria to minimize bias in the selection of studies and data extraction. Any disagreement was resolved by discussion. Scores were assigned to study design characteristics by using a standardized form recommended by the Cochrane library.¹⁴ Other characteristics were also extracted by using a standardized form.

As we all know, for an ideal meta-analysis, it is better that all the studies enrolled are randomized controlled trials

	Vertebrop	lasty	Kyphopl	asty		Odd's Ratio	Odd's Ratio
Study or Subgroup	Events	Total	Events	Tota	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
28.1.1 to disc							
Hiwatashi 2009	62	248	14	114	21.8%	2.38[1.27, 4.47]	
Lovi 2009	8	118	2	36	4.3%	1.24 [0.25, 6.10]	
Movirin2010	3	27	1	46	1.0%	5.63 [0.55, 57.05]	
Santiago 2010	6	30	7	30	8.5%	0.82[0.24, 2.81]	
Yan 2010	9	94	3	98	4.0%	3.35 [0.88, 12.79]	+
Subtotal (95% CI)		517		324	39.7%	2.10 [1.31, 3.37]	•
Total events	88		27				
Heterogeneity: ChF = 3	3.97, df = 4 (P = 0.41); I² = 0%				
Test for overall effect: 2	Z = 3.08 (P =	= 0.002)					
28.1.2 paravertebrai							
Hiwatashi 2009	10	57	6	124	4.7%	4.18 [1.44, 12.16]	
Lovi 2009	10	118	4	36	8.5%	0.74 [0.22, 2.52]	
Santiago 2010	8	30	2	30	2.2%	5.09 [0.98, 26.43]	
Yan 2010	4	94	0	98	0.7%	9.80 [0.52, 184.49]	
Zhou 2008	6	56	3	32	5.2%	1.16 [0.27, 4.99]	
Subtotal (95% CI)		355		320	21.4%	2.36 [1.27, 4.40]	•
Total events	38		15				
Heterogeneity: ChF = 7			i); I² = 44%	6			
Test for overall effect: 2	Z = 2.70 (P =	= 0.007)					
20124-4-1							
28.1.3 total	~	4.0			o 101		_
De Negri 2207	5	10	0	11		23.00 [1.07, 494.57]	
Frankel 2007	2	26	3	20	4.8%	0.47 [0.07, 3.14]	
Kumar 2010	10	28	8	24	0.0%	1.11 [0.35, 3.50]	
Lovi 2009 Maximin 2010	18	118	6	36	11.8%	0.90 [0.33, 2.47]	1
Movirin2010	7	27	4	46	3.3%	3.67 [0.96, 14.02]	
Santiago 2010 Schofer 2009	14 7	30 30	9	30	7.3%	2.04 [0.71, 5.89]	
Yan 2010	13	30 94	2 3	30 98	2.3% 3.8%	4.26 [0.81, 22.53] 5.08 [1.40, 18.46]	
Zhou 2008	6	94 56	3	32	5.2%	1:16 [0.27, 4.99]	
Subtotal (95% CI)	0	391	3	303	38.9%	2,15 [1.35, 3,44]	•
Total events	72	551	30	505	30.370	215[1.53, 344]	•
Heterogeneity: Chr = 1	• =	(P = 0.1)		ov.			
Test for overall effect: 2			57,1 30				
restror overall effect. 2	L – 3.22 (F -	- 0.001)					
Total (95% CI)		1263		947	100.0%	2.18 [1.62, 2.92]	◆
Total events	198		72				
Heterogeneity: ChF = 2	2.48, df = 1	7 (P = 0.	17); l² = 2	4%			
Test for overall effect: 2	Z = 5.21 (P ·	< 0.0000	1)			-	avours experimental Favours control
Test for subaroup diffe	rences: Not	applicat	le			F	avours experimental ravours control

Fig. 5. The forest plots of meta-analysis of cement leakage.

Table 6 Results of meta-analysis of complication outcome measures

Outcomes or subgroups	No. of studies	No. of patients	Statistical method	Effect estimate (95% CI) [†]	P value
(9) Adjacent new vertebral fractures	7	667	OR	1.26 [0.69, 2.29]	>.05
9.1 at 6 months	2	136	OR	0.14 [0.02, 1.21]	>.05
9.2 at 1 year	5	531	OR	1.78 [0.91, 3.49]	>.05
(10) Cement leakage					
10.1 to disc	5	841	OR	2.10 [1.31, 3.37]	<.05*
10.2 paravertebral	5	675	OR	2.36 [1.27, 4.40]	<.05*
10.3 total	9	694	OR	2.15 [1.35, 3.44]	<.05 *

OR, Odds Ratio; CI, confidence interval.

If effect estimate is positive (>0), it means vertebroplasty group is more than kyphoplasty group. If it is negative (<0), it means vertebroplasty group is less than kyphoplasty group. Whether it is significant lies on P value.

*Statistically significant.

[†]Effect estimate.

(RCT) with homogeneity. However, in practice, RCT is very rare, especially for surgery.^{33,34} It is because treatment with surgery is different from that with drugs. Every surgeon has his personal preference and familiarity with the various surgical options. In addition, the patients always take the selection of operation more seriously and seldom agree to receive a randomized surgical option. In this metaanalysis, not only randomized controlled clinical trials, but also quasi-randomized controlled clinical trials, perspective cohort study, and retrospective cohort study were enrolled in this meta-analysis. It would not influence the credibility of the results for this meta-analysis. There were 2 major causes. One was that all the enrolled studies were relatively high-quality studies based on the methodological quality assessment scheme. The other was that almost all the studies reported that the baseline characteristics, such as age, sex, and duration of symptoms, were matched for each group.

We attempted to examine publication bias by using the Funnel plot analysis, because publication bias is a potential limitation of any meta-analysis. In particular, small studies with optimistic results may be published more easily than small studies with unfavorable results. Larger studies with optimistic results may also be published more easily than larger studies with unfavorable results, but this difference usually is smaller. The results show there was no obvious publication bias in this meta-analysis.

Since the late 1980s, 2 minimally invasive surgical treatments, vertebroplasty and kyphoplasty, have been gradually introduced that changed the treatment of OVCF. In 1987, Galibert et al.³⁵ used vertebroplasty for the first time to treat vertebral hemangioma, and later in 1988, PVP was used to treat OVCF. Since then, this technology is being widely used in primary vertebral osteolytic tumors, vertebral metastases, and painful osteoporotic vertebral fractures around the world.^{36,37} Guided by X-Ray, vertebroplasty involves injecting PMMA bone cement into the fractures of the vertebral body percutaneously to enhance the strength and stiffness of the vertebra and prevent further vertebral collapse and deformity, and effectively relieve pain.

PKP was first performed in the 1998³⁸ and involves fracture reduction using inflation bone tamps (balloon) to restore vertebral height. The 2 bone tamps used bilaterally create a void in the vertebral body that can be filled under fine manual control and low pressure with high-viscosity bone cement. Unlike vertebroplasty, PKP aims to not only secure fracture fixation and stabilization but also to correct and prevent the spinal deformity, thereby reducing the negative burden of VCFs.^{39,40} Balloon inflation compacts the cancellous bone and pushes the end plates apart, which might partly restore height and correct angular deformity. Once the balloons have been removed, the resulting void is filled with viscous bone cement to stabilize the vertebral body. The procedure can be done under general anesthesia or conscious sedation, either as a day case, or with an overnight stay, depending on the medical need.

VP has an advantage for certain patients because it usually is a quicker procedure. Usually, it can be performed through a unipedicular approach, which reduces the overall procedure time. This is an important factor for elderly patients with multiple medical problems, who have an increased anesthesia risk, even with conscious sedation.

KP has the advantage of reduced cement leakage. The insertion of the bone tamp before PMMA injection significantly reduces cement leakage. This becomes an important safety factor in fractures with multiple fracture linesand retropulsion, and when a fracture extends into the end plates and the posterior wall. KP is safer than VP for 2 principle reasons: firstly, KP involves cement injection with a lower pressure, and secondly, it is in a more viscous state when injected, which make KP feasible for the treatment of OVCF with vertebral wall deficiency⁴¹ and OVCF nonunion without neurological deficit.⁴² The cement is often injected in a less-viscous state and under high pressures for VP, which often leads to cement extravasation outside of the vertebral body either into the disc space, outside the margins of the body, or into the epidural space. In addition, the creation of the cavity with the balloon during a kyphoplasty facilitates the safe introduction of the cement into this defined cavity. Both procedures carry the risk of cement extravasation; however, there is significantly less risk for kyphoplasty. Compared with the 19.7%-41% cement leakage for VP, the cement leakage for KP is only 7%-10.6%.^{43–45} The lowest cement leakage rate for KP reported is about 2.0% for 1257 patients in a study in which the author used a special injection technique called incremental temperature cement delivery system (ITCDS).⁴⁶

The main limitations of this review are that the demographics and comorbidities of study participants were not reported. These possible sources of heterogeneity could not be examined and most of the studies had suboptimal design which would influence the outcome of this meta-analysis to some extent.

Based on the result of this meta-analysis, we can conclude that pain relief after kyphoplasty is significantly greater than that achieved with vertebroplasty. The benefits can be sustained for at least 2 years. Kyphoplasty can improve the vertebral height and kyphosis angle much more than vertebroplasty with lower occurrence of cement leakage.

References

- Rapado A. General management of vertebral fractures. *Bone* 1996;18: 191S–6S.
- Fast facts on osteoporosis. www.nof.org/professionals/fast_facts_osteo porosis.pdf. Updated 2009.
- Mohit A, Orr D. Percutaneous vertebral augmentation in osteoporotic fractures. *Curr Opin Orthop* 2007;16:221–5.
- Cooper C, Atkinson EJ. Incidence of clinically diagnosed vertebral fractures: A populationbased study in Rochester, Minnesota, 1985– 1989. J Bone Miner Res 1992;7:221–7.
- Convertino VA, Bloomfield SA, Greenlcaf JF. An overview of the issues: Physiological effects of bed rest and rest ricted physical activity. *Med Sci Exerc* 1997;19:187–90.
- Phillips FM. Minimally invasive treatments of osteoporotin vertebral compression fractures. *Spine* 2003;28(15 Suppl):45–53.
- Galibert P, Deramond H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. *Neurochirurgie* 1987;33:166.
- Amar AP, Larsen DW, Esnaashari N, Albuquerque FC, Lavine SD, Teitelbaum GP. Percutaneous transpedicular polymethyl methacrylate vertebroplasty for the treatment of spinal compression fractures. *Neurosurgery* 2001;49:1105–14.
- Yang HL, Zhao L, Liu J, et al. Changes of pulmonary function for patients with osteoporotic vertebral compression fractures after kyphoplasty. J Spinal Disord Tech 2007;20:221–5.
- Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to META-analysis. *Stat Med* 1993;12:2273–84.
- Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in META -analysis: Multivariate approach and META-regression. *Stat Med* 2002;21:589–624.
- Deville WL, Bezemer PD, Bouter LM. Publications on diagnostic test evaluation in family medicine journals: An optimal search strategy. *J Clin Epidemiol* 2000;53:65–9.
- Berlin JA. Does blinding of readers affect the results of METAanalyses? University of Pennsylvania META-analysis Blinding Study Group. *Lancet* 1997;350:185–6.
- Handoll HHG, Vaghela MV, Madhok R. Percutaneous pinning for treating distal radial fractures in adults. *Cochrane Database Syst Rev* 2007(Issue 3), http://dx.doi.org/10.1002/14651858.CD006080.pub2; Art. No.: CD006080.

- Clarke M, Horton R. Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. *Lancet* 2001;357:1728.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology, a proposal for reporting: Meta-analysis of observational studies in epidemiology (MOOSE) group. J Am Med Assoc 2000;283:2008–12.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–8.
- Liu JT, Liao WJ, Tan WC, et al. Balloon kyphoplasty versus vertebroplaty for treatment of osteoporotic vertebral compression fracture: A prosperctive, comprarative, and randomized clinical study. *Osteoporos Int* 2010;21:359–64.
- Kumar K, Nguyen R, Bishop S. A comparative analysis of the results of vertebroplasty and kyphoplasty in osteoporotic vertebral compression fractures. *Neurosurgery* 2010;67:171–88.
- Santiago FR, Abela AP, Álvarez LG, Osuna RMA, Garcia MDMC. Pain and functional outcome after vertebroplasty and kyphoplasty. A comparative study. *Eur J Radiol* 2010;75:108–13.
- Yan D, Duan L, Li J, Soo C, Zhu H, Zhang Z. Comparative study of percutaneous vertebroplasty and kyphoplasty in the treatment of osteoporotic vertebral compression fractures. *Arch Orthop Trauma Surg* 2010;131:645–50.
- Hiwatashi A, Westesson PL, Yoshiura T, et al. Kyphoplasty and vertebroplasty produce the same degree of height restoration. *Am J Neuroradiol* 2009;30(4):669–73.
- Schofer MD, Efe T, Timmesfeld N, Kortmann HR, Quante M. Comparison of kyphoplasty and vertebroplasty in the treatment of fresh vertebral compression fractures. *Arch Orthop Trauma Surg* 2009;129(10):1391–9.
- 24. Lovi A, Teli M, Ortolina A, Costa F, Fornari M, Brayda-Bruno M. Vertebroplasty and kyphoplasty: Complementary techniques for the treatment of painful osteoporotic vertebral compression fractures. A prospective non-randomised study on 154 patients. *Eur Spine* J 2009;18(Suppl 1):S95–101.
- 25. Zhou J, Liu S, Ming J, Peng H, Qiu Bo. Comparison of therapeutic effect between percutaneous vertebroplasty and kyphoplasty on vertebral compression fracture. *Chin J Traumatol* 2008;11(1): 42–4; English Edition.
- Frankel BM, Monroe T, Wang C. Percutaneous vertebral augmentation: An elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. *Spine J* 2007;7(5):575–82.
- De Negri P, Tirri T, Paternoster G, Modano P. Treatment of painful osteoporotic or traumatic vertebral compression fractures by percutaneous vertebral augmentation procedures: A nonrandomized comparison between vertebroplasty and kyphoplasty. *Clin J Pain* 2007;23(5): 425–30.
- Grohs JG, Matzner M, Trieb K, Krepler P. Minimal invasive stabilization of osteoporotic vertebral fractures: A prospective nonrondomized comparison of vertebroplasty and balloon kyphoplasty. *J Spinal Disord Tech* 2005;18(3):238–42.
- Pflugmacher R, Kandziora F, Schröder R, et al. Vertebroplasty and kyphoplasty in osteoporotic fractures of vertebral bodies-a prospective 1-year follow-up analysis. *Fortschr Röntgenstr* 2005;177:1670–6.
- Movrin I, Vengust R, Komadina R. Adjacent vertebral fractures after percutaneous vertebral augmentation of osteoporotic vertebral compression fracture: A comparison of balloon kyphoplasty and vertebroplasty. Arch Orthop Trauma Surg 2010:1–10.
- Röllinghoff M, Siewe J, Zarghooni K, et al. Effectiveness, security and height restoration on fresh compression fractures a comparative prospective study of vertebroplasty and kyphoplasty. *Minim Invasive Neurosurg* 2009;52(5–6):233–7.
- Pilát P, Neckar P, Sauer M. Kyphoplasty and vertebroplasty in the treatment of osteoporotic vertebral fractures. *Osteologicky Bull* 2007;12(1):4–9.
- 33. Ng TT. Meta-analysis in surgery. Arch Surg 2006;141:1125-30.

e57

- Antes G, Diener MK. The role of systematic reviews in evidence-based healthcare. CJEBM 2006;6:467–8.
- Galibert P, Deramond H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. *Neurochirurgie* 1987;33:166.
- 36. Cotten A, Dewatre F, Cortet B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: Effects of the percentage of lesion filling and the leakage of methylmethacrylate at clinical follow-up. *Radiology* 1996;200:525.
- Amar AP, Larsen DW, Esnaashari N, Albuquerque FC, Lavine SD, Teitelbaum GP. Percutaneous transpedicular polymethylmethacrylate vertebroplasty for the treatment of spinal compression fractures. *Neurosurgery* 2001;49:1105–14.
- Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002;20(9):2382–7.
- Lieberman IH, Dudeney S, Reinhardt MK, Bell G. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. *Spine* 2001;26:1631–8.
- 40. Zhi-Yong S, Huan Z, Gui-Zhong W, et al. Kyphoplasty for the treatment of vertebral compression fractures with anterior vertebral

wall destruction: how can we do it better? *Pain Physician* 2012;15: 95–6.

- Zou J, Mei X, Gan M, Wang G, Lu J, Yang H. Is kyphoplasty reliable for osteoporotic vertebral compression fracture with vertebral wall deficiency? *Injury* 2010;41(4):360–4.
- Yang H, Wang G, Liu J, et al. Balloon kyphoplasty in the treatment of osteoporotic vertebral compression fracture nonunion. *Orthopedics* 2010;33(1):24–8.
- Eck JC, Nachtigall D, Huraphreys SC, et al. Comparison of vertebroplaaty and balloon kyphoplasty for treatment of vertebral compression fractures: A meta-analysis of the literature[J]. *Spine J* 2008;8(3): 488–97.
- Hulme PA, Krebs J, Ferguson SJ, et al. Vertebroplasty and kyphoplasty: A systematic review of 69 clinical studies(J). *Spine* 2006;31:1983–2001.
- 45. Majd ME, Farley S, Holt RT. Preliminary outcomes and efficacy of the first 360 consecutive kyphoplasties for the treatment of painful osteoporotic vertebral compression fractures. *Spine J* 2005;5(3): 244–55.
- 46. Wang G, Yang H, Meng B, et al. Analysis on the follow-ups of the osteoporotic vertebral compression fracture treated with balloon kyphoplasty. J Soochow Univ Med Sci 2012;32(6):96–101.